Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...

Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...

Motilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Indian stock markets experienced a sharp downturn Friday, with Sensex and Nifty falling significantly due to persistent foreign investor se...

Indian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...

Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Indian stock markets surged on Monday, with Sensex and Nifty rallying over 1% each, driven by rising hopes of a US-Iran peace deal and fall...

Brokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while re...

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...

Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to c...

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...